The specialised small molecule drug development business, today announced its results for FY June 2019. Sareum’s greatest focus at present is the progression of its two distinct proprietary selective TYK2/JAK1 inhibitors in autoimmune diseases and cancer. SDC 1801 (autoimmune) is the furthest advanced in terms of work completed to move towards clinical trials and has progressed into longer-term toxicology and dose-finding studies, which would form part of the regulatory documentation ne
15 Oct 2019
Proprietary programs gaining increased pharma interest and targeting clinic in 2020. US$5.3m milestone on SRA 737 still remains in sight.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Proprietary programs gaining increased pharma interest and targeting clinic in 2020. US$5.3m milestone on SRA 737 still remains in sight.
Sareum Holdings plc (SAR:LON) | 10.8 0 0.0% | Mkt Cap: 7.71m
- Published:
15 Oct 2019 -
Author:
Derren Nathan -
Pages:
8
The specialised small molecule drug development business, today announced its results for FY June 2019. Sareum’s greatest focus at present is the progression of its two distinct proprietary selective TYK2/JAK1 inhibitors in autoimmune diseases and cancer. SDC 1801 (autoimmune) is the furthest advanced in terms of work completed to move towards clinical trials and has progressed into longer-term toxicology and dose-finding studies, which would form part of the regulatory documentation ne